Posted by Michael Wonder on 19 Nov 2020
Kyowa Kirin announces approval for partial change of rituximab biosimilar received by Sandoz in Japan
18 November 2020 - Kyowa Kirin today announced that Sandoz KK, its strategic partner of the anti-CD20 monoclonal antibody rituximab biosimilar, has received approval for the partial change of rituximab biosimilar for the treatment of acquired thrombotic thrombocytopenic purpura.
The product was recently granted a partial change approval for the treatment of chronic idiopathic thrombocytopenic purpura and as premedication of ibritumomab tiuxetan in September 2020.
